{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:47:50Z","timestamp":1785797270133,"version":"3.56.0"},"reference-count":40,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81774072"],"award-info":[{"award-number":["81774072"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["7202015"],"award-info":[{"award-number":["7202015"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["81774072"],"award-info":[{"award-number":["81774072"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7202015"],"award-info":[{"award-number":["7202015"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Astragaloside IV (AS-IV) is a chemical found in traditional Chinese medicine called Astragalus membranaceus (Fisch.) Bunge that has antitumor properties. However, the roles and mechanisms of AS-IV in uterine leiomyomas (ULMs) are unclear. The immunosuppressive enzyme indoleamine-2,3-dioxygenase-1 (IDO1) is involved in tumor formation. IDO1 is a new and reliable prognostic indicator for several cancers. In this work, AS-IV was applied to ULM cells in various concentrations. CCK-8, immunofluorescence, and flow cytometry were used to examine the proliferation and apoptosis of ULM cells caused by AS-IV. After lentiviral vector transduction with IDO1 short hairpin RNA (shRNA), the knockdown and overexpression of IDO1 were stable in ULM cells. To verify the antitumor effect of AS-IV in vivo, we established a rat model of uterine leiomyoma. HE staining, Masson staining, and transmission electron microscopy were used to observe pathological changes in the uterus, and the levels of serum sex hormones were measured by radio immune assay (RIA). The levels of CD3+T, CD4+T, and CD25+ Foxp3+Treg in rat peripheral blood were detected by flow cytometry. Western blotting and immunohistochemistry were used to examine protein expression. We found that AS-IV dramatically increased the apoptotic rate of ULM cells and reduced viability in a time- and dosage-dependent manner. After sh-IDO1 lentiviral transfection, we discovered that knocking down IDO1 reversed the effects of AS-IV on ULM cell proliferation and autophagy. We also found that AS-IV can effectively inhibit the growth of ULMs in vivo. AS-IV may promote apoptosis and autophagy in ULMs by activating PTEN\/PI3K\/AKT signaling through inhibition of IDO1. These findings imply that AS-IV exerts antifibroid effects, and the underlying mechanism may be IDO1, which is involved in proliferation, apoptosis, and autophagy.<\/jats:p>","DOI":"10.3390\/cancers14184424","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T20:52:25Z","timestamp":1663015945000},"page":"4424","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Astragaloside IV Inhibits the Proliferation of Human Uterine Leiomyomas by Targeting IDO1"],"prefix":"10.3390","volume":"14","author":[{"given":"Tiantian","family":"Qiu","sequence":"first","affiliation":[{"name":"School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"Li","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ren","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Luo","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.fertnstert.2007.01.093","article-title":"Etiology, symptomatology, and diagnosis of uterine myomas","volume":"87","author":"Parker","year":"2007","journal-title":"Fertil. Steril."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/humupd\/dmv030","article-title":"Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth","volume":"21","author":"Commandeur","year":"2015","journal-title":"Hum. Reprod. Update"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.jvir.2014.05.012","article-title":"Incidence of additional treatments in women treated with MR-guided focused US for symptomatic uterine fibroids: Review of 138 patients with an average follow-up of 2.8 years","volume":"25","author":"Gorny","year":"2014","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5582\/bst.2015.01019","article-title":"The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer","volume":"9","author":"Qi","year":"2015","journal-title":"Biosci. Trends"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/bs.apha.2019.08.002","article-title":"Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects","volume":"87","author":"Zhang","year":"2020","journal-title":"Adv. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3892\/ijmm.2021.4846","article-title":"Molecular mechanisms of astragaloside-IV in cancer therapy (Review)","volume":"47","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2741\/4738","article-title":"Astragaloside IV inhibits human colorectal cancer cell growth","volume":"24","author":"Sun","year":"2019","journal-title":"Front Biosci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pharep.2017.07.001","article-title":"Chemosensitive effects of Astragaloside IV in osteosarcoma cells via induction of apoptosis and regulation of caspase-dependent Fas\/FasL signaling","volume":"69","author":"Hu","year":"2017","journal-title":"Pharm. Rep."},{"key":"ref_9","first-page":"2341","article-title":"Astragaloside induces gastric MGC-803 cells apoptosis by inhibiting AKT and NF-KB pathway","volume":"19","author":"Ying","year":"2018","journal-title":"Int. J. Lab. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.biopha.2018.03.127","article-title":"Astragaloside IV inhibits cell proliferation of colorectal cancer cell lines through down-regulation of B7-H3","volume":"102","author":"Wang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_11","first-page":"2975","article-title":"Astragaloside IV inhibits the invasion and metastasis of SiHa cervical cancer cells via the TGF-\u03b21-mediated PI3K and MAPK pathways","volume":"41","author":"Zhang","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in Signaling and Disease: Beyond Discovery and Development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s11658-020-00218-9","article-title":"Quantitative proteomics analysis of differentially expressed proteins induced by astragaloside IV in cervical cancer cell invasion","volume":"25","author":"Xia","year":"2020","journal-title":"Cell Mol. Biol. Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.intimp.2017.05.017","article-title":"Immune regulation mechanism of Astragaloside IV on RAW264.7 cells through activating the NF-\u03baB\/MAPK signaling pathway","volume":"49","author":"Li","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3389\/fimmu.2013.00382","article-title":"Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer","volume":"4","author":"Goyne","year":"2013","journal-title":"Front Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.3748\/wjg.v23.i13.2286","article-title":"Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma","volume":"23","author":"Asghar","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e981457","DOI":"10.4161\/2162402X.2014.981457","article-title":"Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival","volume":"4","author":"Ferns","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1078-0432.CCR-16-0150","article-title":"Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer","volume":"23","author":"Schalper","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1593\/neo.04658","article-title":"Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer","volume":"7","author":"Astigiano","year":"2005","journal-title":"Neoplasia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","article-title":"Indoleamine 2,3 dioxygenase and metabolic control of immune responses","volume":"34","author":"Munn","year":"2013","journal-title":"Trends Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1172\/JCI31178","article-title":"Indoleamine 2,3-dioxygenase and tumor-induced tolerance","volume":"117","author":"Munn","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1053\/j.gastro.2013.05.002","article-title":"IDO1 metabolites activate \u03b2-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice","volume":"145","author":"Thaker","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"637024","DOI":"10.3389\/fonc.2021.637024","article-title":"Curdione Induces Antiproliferation Effect on Human Uterine Leiomyosarcoma via Targeting IDO1","volume":"11","author":"Wei","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: From pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"031001","DOI":"10.1088\/1478-3975\/13\/3\/031001","article-title":"Apoptosis: Its origin, history, maintenance and the medical implications for cancer and aging","volume":"13","author":"Kaczanowski","year":"2016","journal-title":"Phys. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.fertnstert.2009.03.100","article-title":"Changes related to phosphatidylinositol 3-kinase\/Akt signaling in leiomyomas: Possible involvement of glycogen synthase kinase 3alpha and cyclin D2 in the pathophysiology","volume":"93","author":"Karra","year":"2010","journal-title":"Fertil. Steril."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1248\/bpb.30.1624","article-title":"PTEN: Its deregulation and tumorigenesis","volume":"30","author":"Maehama","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/156800908784293659","article-title":"The PTEN\/PI3K\/AKT signalling pathway in cancer, therapeutic implications","volume":"8","author":"Carnero","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1210\/jc.2008-2093","article-title":"Progestins activate the AKT pathway in leiomyoma cells and promote survival","volume":"94","author":"Hoekstra","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.3892\/ijo.2016.3486","article-title":"The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway","volume":"48","author":"Wang","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.2438","article-title":"Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido","volume":"17","author":"Balachandran","year":"2011","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/0008-5472.CAN-18-0668","article-title":"IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis","volume":"79","author":"Bishnupuri","year":"2019","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1248\/cpb.c13-00556","article-title":"Astragaloside IV inhibits doxorubicin-induced cardiomyocyte apoptosis mediated by mitochondrial apoptotic pathway via activating the PI3K\/Akt pathway","volume":"62","author":"Jia","year":"2014","journal-title":"Chem. Pharm. Bull."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: Current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.semcancer.2017.11.019","article-title":"Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy","volume":"52","author":"Osmani","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-18-2882","article-title":"Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis","volume":"25","author":"Labadie","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00432-014-1744-x","article-title":"Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO","volume":"140","author":"Zhang","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1158\/0008-5472.CAN-09-3170","article-title":"Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity","volume":"70","author":"Gu","year":"2010","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7325","DOI":"10.4049\/jimmunol.176.12.7325","article-title":"Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2\/neu transgenic mice bearing advanced spontaneous tumors","volume":"176","author":"Nair","year":"2006","journal-title":"J. Immunol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/18\/4424\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:29:44Z","timestamp":1760142584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/18\/4424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":40,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["cancers14184424"],"URL":"https:\/\/doi.org\/10.3390\/cancers14184424","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]}}}